Dong-A ST to develop immuno-oncology drug candidates with AstraZeneca

Ref: The Korea Herald
  • Dong-A ST announced it had inked a deal with AstraZeneca to jointly develop immuno-oncology drug candidates, The Korea Herald reported Friday.

  • In the deal, the drugmakers will collaborate in the development of three oncology research projects led by AstraZeneca.

  • The companies will jointly own any intellectual property developed in the deal, with each drugmaker holding options to acquire exclusive rights to the findings at a later stage.

    "This collaboration will allow AstraZeneca and Dong-A ST to combine expertise and generate and progress compounds that target mutual points of interest in the most efficient way," said Susan Galbraith, head of AstraZeneca's IMED oncology unit.

  • Financial terms of the deal were not released.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>